RT Journal Article
SR Electronic
T1 Serological surveillance of SARS-CoV-2: trends and humoral response in a cohort of public health workers
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.10.21.20216689
DO 10.1101/2020.10.21.20216689
A1 Ross J Harris
A1 Heather J Whitaker
A1 Nick J Andrews
A1 Felicity Aiano
A1 Zahin Amin-Chowdhury
A1 Jessica Flood
A1 Ray Borrow
A1 Ezra Linley
A1 Shazaad Ahmad
A1 Lorrain Stapley
A1 Bassam Hallis
A1 Gayatri Amirthalingam
A1 Ben Parker
A1 Alex Horsley
A1 Timothy J G Brooks
A1 Kevin E Brown
A1 Mary E Ramsay
A1 Shamez Ladhani
YR 2020
UL http://medrxiv.org/content/early/2020/10/23/2020.10.21.20216689.abstract
AB Background There is considerable debate about the rate of antibody waning after SARS-CoV-2 infection, raising questions around long-term immunity following both natural infection and vaccination. We undertook prospective serosurveillance in a large cohort of healthy adults from the start of the epidemic in England.Methods The serosurveillance cohort included office and laboratory-based staff and healthcare workers in 4 sites in England, who were tested monthly for SARS-CoV-2 spike protein and nucleoprotein IgG between 23rd March and 20th August 2020. Antibody levels from 21 days after a positive test were modelled using mixed effects regression models.Findings In total, 2247 individuals were recruited and 2014 (90%) had 3-5 monthly antibody tests. Overall, 272 (12.1%) of individuals had at least one positive/equivocal spike protein IgG result, with the highest proportion in a hospital site (22%), 14% in London and 2.1% in a rural area. Results were similar for nucleoprotein IgG. Following a positive result, 39/587 (6.6%) tested negative for nucleoprotein IgG and 52/515 (10.1%) for spike protein IgG. Nucleoprotein IgG declined by 6.4% per week (95% CI, 5.5-7.4%; half-life, 75 [95% CI, 66-89] days) and spike protein IgG by 5.8% (95% CI, 5.1-6.6%; half-life, 83 [95% CI, 73-96] days).Conclusions Over the study period SARS-CoV-2 seropositivity was 8-10% overall and up to 21% in clinical healthcare workers. In seropositive individuals, nucleoprotein and spike protein IgG antibodies declined with time after infection and 50% are predicted to fall below the positive test threshold after 6 months.Funding PHECompeting Interest StatementThe authors have declared no competing interest.Funding StatementThis research was internally funded by Public Health England. BP is supported by the NIHR Manchester Biomedical Research Centre. At no time did any other author or their institutions receive payment or services from a third party for any aspect of the submitted work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by PHE Research Support and Governance Office (R&D REGG Ref NR 0190)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSharing of individual-level data is not permitted under the study protocol, although provision of aggregated data for specific purposes will be considered on request.